GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (NAS:SLS) » Definitions » E10

SELLAS Life Sciences Group (SELLAS Life Sciences Group) E10 : $-3,321.72 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

SELLAS Life Sciences Group's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.250. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-3,321.72 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 28.80% per year. During the past 5 years, the average E10 Growth Rate was 23.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of SELLAS Life Sciences Group was 28.80% per year. The lowest was 17.20% per year. And the median was 19.10% per year.

As of today (2024-04-27), SELLAS Life Sciences Group's current stock price is $1.46. SELLAS Life Sciences Group's E10 for the quarter that ended in Dec. 2023 was $-3,321.72. SELLAS Life Sciences Group's Shiller PE Ratio of today is .


SELLAS Life Sciences Group E10 Historical Data

The historical data trend for SELLAS Life Sciences Group's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group E10 Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11,386.30 -9,201.12 -8,543.68 -6,459.11 -3,321.72

SELLAS Life Sciences Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6,459.11 -6,140.91 -5,776.33 -5,393.31 -3,321.72

Competitive Comparison of SELLAS Life Sciences Group's E10

For the Biotechnology subindustry, SELLAS Life Sciences Group's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Shiller PE Ratio falls into.



SELLAS Life Sciences Group E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SELLAS Life Sciences Group's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.25/129.4194*129.4194
=-0.250

Current CPI (Dec. 2023) = 129.4194.

SELLAS Life Sciences Group Quarterly Data

per share eps CPI Adj_EPS
201403 -600.006 99.695 -778.904
201406 -5,100.050 100.560 -6,563.730
201409 -1,500.020 100.428 -1,933.047
201412 -1,800.020 99.070 -2,351.451
201503 -2,400.020 99.621 -3,117.905
201506 -3,000.030 100.684 -3,856.248
201509 -3,300.030 100.392 -4,254.224
201512 -3,600.040 99.792 -4,668.843
201603 -2,760.030 100.470 -3,555.290
201606 870.009 101.688 1,107.269
201609 -990.010 101.861 -1,257.856
201612 -735.007 101.863 -933.847
201703 -181.500 102.862 -228.360
201706 -225.000 103.349 -281.757
201709 -225.002 104.136 -279.632
201712 15.329 104.011 19.074
201803 -83.500 105.290 -102.636
201806 -63.000 106.317 -76.690
201809 -26.750 106.507 -32.505
201812 -30.243 105.998 -36.926
201903 -11.120 107.251 -13.419
201906 -6.330 108.070 -7.581
201909 -2.680 108.329 -3.202
201912 -1.460 108.420 -1.743
202003 -0.660 108.902 -0.784
202006 -0.660 108.767 -0.785
202009 -0.530 109.815 -0.625
202012 -0.280 109.897 -0.330
202103 -0.160 111.754 -0.185
202106 -0.300 114.631 -0.339
202109 -0.450 115.734 -0.503
202112 -0.420 117.630 -0.462
202203 -1.050 121.301 -1.120
202206 -0.410 125.017 -0.424
202209 -0.340 125.227 -0.351
202212 -0.430 125.222 -0.444
202303 -0.470 127.348 -0.478
202306 -0.310 128.729 -0.312
202309 -0.330 129.860 -0.329
202312 -0.250 129.419 -0.250

Add all the adjusted EPS together and divide 10 will get our e10.


SELLAS Life Sciences Group  (NAS:SLS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


SELLAS Life Sciences Group E10 Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group (SELLAS Life Sciences Group) Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Executives
Angelos M. Stergiou director, officer: President and CEO C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583
Barbara A Wood officer: EVP, Gen. Counsel, Corp. Sec. 58 S SERVICE RD, MELVILLE NY 11747
John Thomas Burns officer: VP, Finance & Corp Controller 16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Robert Francomano officer: Chief Commercial Officer C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022
Nicholas J. Sarlis officer: Chief Medical Officer and SVP C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583
Stephen F Ghiglieri director C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David A Scheinberg director 325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
John Varian director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund` 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Equilibria Capital Management Ltd 10 percent owner O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08

SELLAS Life Sciences Group (SELLAS Life Sciences Group) Headlines

From GuruFocus

SELLAS Life Sciences Announces Proposed Underwritten Public Offering

By sperokesalga sperokesalga 02-23-2023